Table 1.
Analysis of data available for SAGE vaccine decisions according to WHO Guidelines document criteria
| Intervention | Hib | PCV | RV | HPV | IPTi |
|---|---|---|---|---|---|
| Year of licensing | 1988 | 2000 | 2004 | 2006 | NA |
| Safety and efficacy in relevant populations | |||||
| Industrialized countries only | <1998 | 1999 | 2004 | 2006 | NA |
| Range of countries, missing information | 1998 | 2003 | 2005 | 2007 | 2006 |
| All data available | 2006 | 2005 | 2009 | 2008 | 2009 |
| Implications for costs and population health | |||||
| Impact on disease addressed | 2005 | 2005 | 2004 | 2007 | 2004 |
| Demand, supply, financing addressed | 2006 | 2006 | 2005 | 2008 | 2009 |
| All addressing including other public health | 2006 | 2006 | -- | 2009 | 2009 |
| Localization of data | |||||
| Logistics issues addressed | NA | -- | -- | 2007 | 2006 |
| All delivery strategies addressed | 2003 | 2003 | 2005 | 2008 | 2009 |
| Successful demonstration project | 2005 | NA | 2006 | 2008 | 2009 |
| Date of global recommendation in WHO position paper | Nov 2006 | Mar 2007 | Aug 2007 (limited), Jun 2009 | Jun 2009 | Oct 2009 |
NA = not applicable; -- = not yet completed